These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32741916)

  • 1. Screening, Synthesis, and Evaluation of Novel Isoflavone Derivatives as Inhibitors of Human Golgi β-Galactosidase.
    Miura K; Onodera C; Takagi M; Koyama R; Hirano T; Nishio T; Hakamata W
    Chem Pharm Bull (Tokyo); 2020; 68(8):753-761. PubMed ID: 32741916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high-throughput, nonisotopic, competitive binding assay for kinases using nonselective inhibitor probes (ED-NSIP).
    Vainshtein I; Silveria S; Kaul P; Rouhani R; Eglen RM; Wang J
    J Biomol Screen; 2002 Dec; 7(6):507-14. PubMed ID: 14599348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of 6-C-alkyl-DMDP type nanomolar inhibitors of β-galactosidase and β-glucosidase based on broussonetine S and related derivatives.
    Gao FT; Wu QK; Zhang M; Shimadate Y; Qian G; Song YY; Kato A; Li YX; Jia YM; Fleet GWJ; Yu CY
    Eur J Med Chem; 2024 Sep; 275():116570. PubMed ID: 38878517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Guanidino Derivatives of 1,5-Dideoxy-1,5-imino-d-xylitol are Potent, Selective, and Stable Inhibitors of β-Glucocerebrosidase.
    Sevšek A; Šrot L; Rihter J; Čelan M; van Ufford LQ; Moret EE; Martin NI; Pieters RJ
    ChemMedChem; 2017 Apr; 12(7):483-486. PubMed ID: 28328014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of C-5a-chain extended derivatives of 4-epi-isofagomine: Powerful β-galactosidase inhibitors and low concentration activators of GM1-gangliosidosis-related human lysosomal β-galactosidase.
    Thonhofer M; Weber P; Santana AG; Fischer R; Pabst BM; Paschke E; Schalli M; Stütz AE; Tschernutter M; Windischhofer W; Withers SG
    Bioorg Med Chem Lett; 2016 Mar; 26(5):1438-42. PubMed ID: 26838810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological properties of D- and L-1-deoxyazasugars.
    Kato A; Kato N; Kano E; Adachi I; Ikeda K; Yu L; Okamoto T; Banba Y; Ouchi H; Takahata H; Asano N
    J Med Chem; 2005 Mar; 48(6):2036-44. PubMed ID: 15771446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to β-galactosidase mutations: Improved synthesis and biological investigations.
    Front S; Almeida S; Zoete V; Charollais-Thoenig J; Gallienne E; Marmy C; Pilloud V; Marti R; Wood T; Martin OR; Demotz S
    Bioorg Med Chem; 2018 Nov; 26(20):5462-5469. PubMed ID: 30270003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iminosugar-based galactoside mimics as inhibitors of galactocerebrosidase: SAR studies and comparison with other lysosomal galactosidases.
    Biela-Banaś A; Oulaïdi F; Front S; Gallienne E; Ikeda-Obatake K; Asano N; Wenger DA; Martin OR
    ChemMedChem; 2014 Dec; 9(12):2647-52. PubMed ID: 25377381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Senescence-associated beta-galactosidase is lysosomal beta-galactosidase.
    Lee BY; Han JA; Im JS; Morrone A; Johung K; Goodwin EC; Kleijer WJ; DiMaio D; Hwang ES
    Aging Cell; 2006 Apr; 5(2):187-95. PubMed ID: 16626397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (5aR)-5a-C-Pentyl-4-epi-isofagomine: A powerful inhibitor of lysosomal β-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B.
    Front S; Biela-Banaś A; Burda P; Ballhausen D; Higaki K; Caciotti A; Morrone A; Charollais-Thoenig J; Gallienne E; Demotz S; Martin OR
    Eur J Med Chem; 2017 Jan; 126():160-170. PubMed ID: 27750150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, biological evaluation and molecular docking studies of flavone and isoflavone derivatives as a novel class of KSP (kinesin spindle protein) inhibitors.
    Dong JJ; Li QS; Liu ZP; Wang SF; Zhao MY; Yang YH; Wang XM; Zhu HL
    Eur J Med Chem; 2013; 70():427-33. PubMed ID: 24184776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts.
    Fantur K; Hofer D; Schitter G; Steiner AJ; Pabst BM; Wrodnigg TM; Stütz AE; Paschke E
    Mol Genet Metab; 2010 Jul; 100(3):262-8. PubMed ID: 20409738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific alpha-galactosidase inhibitors, N-methylcalystegines--structure/activity relationships of calystegines from Lycium chinense.
    Asano N; Kato A; Miyauchi M; Kizu H; Tomimori T; Matsui K; Nash RJ; Molyneux RJ
    Eur J Biochem; 1997 Sep; 248(2):296-303. PubMed ID: 9346281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of photoswitchable inhibitors for β-galactosidase.
    Rustler K; Mickert MJ; Nazet J; Merkl R; Gorris HH; König B
    Org Biomol Chem; 2018 Oct; 16(40):7430-7437. PubMed ID: 30264846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells.
    Kurz DJ; Decary S; Hong Y; Erusalimsky JD
    J Cell Sci; 2000 Oct; 113 ( Pt 20)():3613-22. PubMed ID: 11017877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement for GM1-gangliosidosis: Uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase:RTB lectin fusion.
    Condori J; Acosta W; Ayala J; Katta V; Flory A; Martin R; Radin J; Cramer CL; Radin DN
    Mol Genet Metab; 2016 Feb; 117(2):199-209. PubMed ID: 26766614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of human Golgi β-galactosidase with no identified glycosidase using a QMC substrate design platform for exo-glycosidase.
    Miura K; Hakamata W; Tanaka A; Hirano T; Nishio T
    Bioorg Med Chem; 2016 Mar; 24(6):1369-75. PubMed ID: 26875935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of beta-galactosidase mutations on the expression of the canine lysosomal multienzyme complex.
    Kreutzer R; Kreutzer M; Sewell AC; Techangamsuwan S; Leeb T; Baumgärtner W
    Biochim Biophys Acta; 2009 Oct; 1792(10):982-7. PubMed ID: 19607915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific determination of beta-galactocerebrosidase activity via competitive inhibition of beta-galactosidase.
    Martino S; Tiribuzi R; Tortori A; Conti D; Visigalli I; Lattanzi A; Biffi A; Gritti A; Orlacchio A
    Clin Chem; 2009 Mar; 55(3):541-8. PubMed ID: 19147730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.